CellCeutix pharmaceutical company

I am very encouraged that the company's lead chemotherapy compound, Kevetrin (TM), has shown activity in animal models of drug resistant lung cancers. Lung cancer causes more deaths annually in Western countries than breast, colorectal and prostate cancers combined. I look forward to contributing to the development of Kevetrin and other Cellceutix compounds."

Krishna Menon, President and Chief Scientific Officer, stated: "Dr. Danishefsky is one of the most well-respected chemists in the world having made many significant contributions in the field of cancer research. Having him join our Scientific Advisory Board will help us immensely in our compound development research efforts. He will be an excellent fit for our Board."

Dr. Danishefsky is an internationally recognized leader in chemistry, specializing in the synthesis of biologically active organic compounds. Dr. Danishefsky earned his Ph.D. in chemistry from Harvard. He spent 14 years at Yale University where he rose to the rank of Sterling Professor of Chemistry, the highest academic rank at Yale University, awarded to a tenured faculty member considered one of the best in his or her field. By 1991 he was also sharing his time with Memorial Sloan-Kettering Cancer Center as director of the Laboratory for Cancer Research Bioorganic Chemistry, becoming chair in 1993. He accepted an appointment as professor at Columbia University in 1993, and now conducts research at both institutions.

AWARDS
Shared the distinguished Wolf Award and $100,000 Prize, with Gilbert Stork
American Chemical Society's Guenther Award
Aldrich Award for Creative Work in Synthetic Organic Chemistry
Benjamin Franklin Medal in Chemistry
National Academy of Sciences' NAS Award in Chemical Sciences
Cope Medal - American Chemical Society
And numerous other awards.